Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI)

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Psychology

Background:

• Cognitive dysfunction is a pervasive issue in major depressive disorder (MDD), affecting multiple cognitive domains.
• This cognitive impairment significantly impacts patient outcomes, workplace disability, and societal perspectives.
• Addressing cognitive function is crucial for comprehensive MDD management.

Purpose of the Study:

• To establish the rationale for evaluating, measuring, and treating cognitive function in adults with MDD.
• To highlight the importance of cognitive function as a determinant of health outcomes.
• To review current evidence on interventions for cognitive dysfunction in MDD.

Main Methods:

• Review of existing evidence on cognitive dysfunction in MDD.
• Analysis of studies investigating the effects of specific antidepressants on cognitive measures.
• Examination of validated tools for cognitive assessment in MDD.

Main Results:

• Cognitive dysfunction in MDD is a key mediator of workplace disability.
• Vortioxetine demonstrates multidomain cognitive benefits, while duloxetine shows improvements in memory acquisition and recall.
• Systematic evaluation for both objective and subjective cognitive dysfunction is recommended for all MDD patients.

Conclusions:

• Interventions specifically targeting cognitive function are likely to enhance functional recovery in MDD.
• Clinicians should utilize validated tools like the THINC-it tool for patient evaluation.
• Preventing cognitive impairment in MDD is a critical therapeutic priority, with vortioxetine and duloxetine showing benefits.